Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Technical Report
  • Published:

Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy

Bone Marrow Transplantation volume 54, pages 969–972 (2019)Cite this article

Subjects

Abstract

Adoptive transfer of T cells modified to express chimeric antigen receptors (CARs) targeting CD19 (CART19s) has demonstrated impressive results in treating B-cell malignancies. Although CART19-induced complications have been gradually recognized, local cytokine-release syndrome (CRS) at particular parts of the body has not been extensively studied. In this paper, we firstly present a successfully treated case of severe dyspnea caused by the rapid enlargement of cervical lymph node following CART19 therapy in a relapsed/refractory DLBCL patient, with emphasis on the recognition, workup, and treatment. This report reminds for a careful evaluation and observation of the pre-existing mass, which could enlarge rapidly again as a result of CRS and be life threatening, in the CART therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A.Flowers CR, 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–59.

    Google Scholar 

  2. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA.et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;377:2531–44.

  3. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H.et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Med. 2018;378:439–48.

    Article  CAS  Google Scholar 

  4. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö.et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. New Engl J Med. 2017;377:2545–54.

    Article  CAS  Google Scholar 

  5. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25–ra25.

    Article  Google Scholar 

  6. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. How I treat: current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.

  7. Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol & Oncol. 2018;11:35.

    Article  Google Scholar 

  8. Hu Y, Wang J, Pu C, Zhao K, Cui Q, Wei G, et al. Delayed terminal ileal perforation in a relapsed/refractory B-cell lymphoma patient with rapid remission following chimeric antigen receptor T-cell therapy. Cancer Res Treat. 2018;50:1462–66.

    Article  Google Scholar 

  9. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer discov. 2016;6:664–79.

  10. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–48.

    Article  CAS  Google Scholar 

  11. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018;23:943–47.

    Article  CAS  Google Scholar 

  12. Lee D, Gardner R, Porter D. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2016;128:1533.

    Article  Google Scholar 

  13. Özdemir E,St, John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ.et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8 + T cells. Blood. 2002;100:3690–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from 973 Program (2015CB964900), the Natural Science Foundation of China (81470341, 81770201, 81730008), Key Project of Science and Technology Department of Zhejiang Province (2018C03016-2, 2015C03G2150011), and Zhejiang public welfare foundation (GF18H180002).

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    Aiyun Jin, Jingjing Feng, Zhudan Wang, Li Jiang, Yongxian Hu & He Huang

  2. Institute of Hematology, Zhejiang University, Hangzhou, China

    Aiyun Jin, Jingjing Feng, Zhudan Wang, Li Jiang, Yongxian Hu & He Huang

  3. Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China

    Aiyun Jin, Jingjing Feng, Zhudan Wang, Li Jiang, Yongxian Hu & He Huang

  4. PET/CT Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    Kui Zhao

Authors
  1. Aiyun Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingjing Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhudan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yongxian Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kui Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. He Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to He Huang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, A., Feng, J., Wang, Z. et al. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transplant 54, 969–972 (2019). https://doi.org/10.1038/s41409-018-0412-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0412-1

This article is cited by

Search

Advanced search

Quick links